Eli Lilly strikes $1.3 billion deal to buy gene-editing startup Verve Therapeutics, companies say

Eli Lilly is set to acquire Verve Therapeutics for up to $1.3 billion, including a near $1 billion upfront payment and $300 million in milestone payments, representing a 67.5% premium on Verve's last closing price and driving Verve's shares up 77.7% premarket. The acquisition expands Lilly's gene-editing portfolio beyond its core weight-loss and diabetes drugs, specifically targeting Verve's gene-editing therapies for reducing high cholesterol in heart disease patients; Lilly shares were down 1% pre-bell.

Analysis

Eli Lilly's definitive agreement to acquire Verve Therapeutics for up to $1.3 billion, featuring a $10.5 per share cash offer that represents a 67.5% premium to Verve's last closing price, signifies a strategic expansion of Lilly's capabilities into the gene-editing domain. The transaction structure, which includes nearly $1 billion as an upfront payment and an additional $300 million contingent upon Verve achieving specific clinical milestones, highlights Lilly's intent to diversify its portfolio beyond its current blockbuster weight-loss and diabetes drugs. This acquisition builds on an existing collaboration between the two companies aimed at developing gene-editing therapies targeting the PCSK9, ANGPTL3, and LPA genes to manage high cholesterol in individuals with heart disease. The market responded with a 77.7% surge in Verve's premarket share price, indicative of the substantial acquisition premium, whereas Eli Lilly's shares saw a modest 1% decline pre-bell, a typical market reaction for an acquiring company. This deal aligns with Lilly's established strategy of incorporating external innovation, particularly in cutting-edge therapeutic areas like gene editing, to secure future growth drivers.

Key Decisions for Investors

• Investors should recognize Eli Lilly's acquisition of Verve Therapeutics as a strategic maneuver to enter the high-potential gene-editing sector, specifically targeting cardiovascular diseases, which could offer significant long-term growth avenues distinct from its current primary revenue sources.
• The $300 million in milestone-contingent payments within the Verve deal structure emphasizes that the ultimate value accretion for Eli Lilly shareholders will depend on successful clinical development and trial outcomes, warranting close monitoring of R&D progress.
• For Verve Therapeutics shareholders, the acquisition at a 67.5% premium delivers a substantial and immediate return, with the nearly $1 billion upfront cash payment significantly mitigating transaction risk and crystallizing value.